Clinical trials: Large B-Cell Lymphoma
Lymphoma
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden
The purpose of this study is to assess in a prospective multicentric study (Phase III) the introduction of a monoclonal antibody directed against B-cells associated with a standard therapy including chemotherapy and…
- Trial name
- NCT00136552
- Testing
- rituximab
- Where
- 5 sites in Belgium, France
- Volunteers
- 360 people
- Sponsor
- Lymphoma Study Association
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
This phase I/II trial studies the best dose and side effects of mogamulizumab in combination with pembrolizumab and to see how well they work in treating patients with diffuse large B cell lymphoma that have come back after a…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03309878
- Testing
- Mogamulizumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Biomarkers in Patients With Diffuse Large B-Cell Lymphoma Treated With Combination Chemotherapy With or Without Rituximab
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Trial name
- NCT01131208
- Testing
- gene expression analysis, laboratory biomarker analysis
- Volunteers
- 200 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Lymphoma, Large B-Cell, Diffuse
Durvalumab in DLBCL After Autologous Transplant
The trial assess the progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.
- Trial name
- IDA-D (NCT03241017)
- Testing
- Durvalumab
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
This phase II trial studies how well tipifarnib works in treating patients with relapsed or refractory non-Hodgkin's lymphoma. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma
- Trial name
- NCT00082888
- Testing
- Laboratory Biomarker Analysis, Tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
This phase II trial is studying how well rituximab together with ifosfamide, carboplatin, and etoposide works in treating young patients with recurrent or refractory non-Hodgkin's lymphoma or acute lymphoblastic leukemia.
- Conditions
- B-cell Childhood Acute Lymphoblastic Leukemia, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma
- Trial name
- NCT00058461
- Testing
- ifosfamide, etoposide, rituximab
- Where
- United States
- Volunteers
- 82 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00019656
- Testing
- perifosine
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase 1/2, multicenter, open-label study to evaluate the efficacy, and safety of various combinations with selinexor in participants with RR DLBCL. The study will be conducted in two phases: Phase 1 and 2.
- Trial name
- NCT04607772
- Testing
- Selinexor, Rituximab, Bendamustine
- Where
- 18 sites in United States
- Sponsor
- Karyopharm Therapeutics Inc
Leukemia, Lymphoma
Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic Cancer
RATIONALE: Giving chemotherapy and total body irradiation before a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00028730
- Testing
- anti-thymocyte globulin, filgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lymphoma, Non-Hodgkin, B-cell Lymphoma
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies.
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- BAF_FRontier-1 (NCT07101328)
- Testing
- LY4152199 - IV
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 215 people
- Sponsor
- Eli Lilly and Company
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.
Diffuse Large B Cell Lymphoma
Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+
The purpose of this study is to compare the efficacy of R2-miniCHOP (Sub-cutaneous Rituximab-miniCHOP + lenalidomide) and R-miniCHOP (Sub-cutaneous Rituximab-miniCHOP) in patients aged 80 years old or more with not previously…
- Trial name
- NCT02128061
- Testing
- Lenalidomide, Rituximab
- Where
- 97 sites in Belgium, France
- Volunteers
- 250 people
- Sponsor
- The Lymphoma Academic Research Organisation
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells and prepares the patient's…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis
- Trial name
- NCT00309842
- Testing
- filgrastim, cyclophosphamide, cyclosporine
- Where
- 2 sites in United States
- Volunteers
- 213 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma
This is an open-label, single-arm study to treat the adult R/R Large B-cell Lymphoma subjects with Relmacabtagene autoleucel (relma-cel) in China.
- Trial name
- NCT06149169
- Testing
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma
This phase 1 study will investigate the safety, tolerability, pharmacokinetic, pharmacodynamic, and clinical activity of AZD0486, a CD19 x CD3 T-cell engaging bispecific antibody, in subjects with B-cell non-Hodgkin lymphoma…
- Conditions
- B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT04594642
- Testing
- AZD0486 IV
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 226 people
- Sponsor
- AstraZeneca
Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma
This phase I/Ib trial studies the side effects and best dose of parsaclisib with or without polatuzumab-vedotin (Pola) plus the standard drug therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate…
- Conditions
- Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04323956
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Parsaclisib
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Diffuse Large B-Cell Lymphoma (DLBCL)
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
This study will treat patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). It will assess the anti-tumor efficacy and safety of birelentinib plus rituximab, cyclophosphamide, doxorubicin, vincristine, and…
- Trial name
- NCT07712588
- Testing
- Birelentinib, Rituximab, Cyclophosphamid
- Where
- 5 sites in China
- Volunteers
- 880 people
- Sponsor
- Dizal Pharmaceuticals
Intravascular Large B-Cell Lymphoma
Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma
This is a prospective single-arm phase II study, and the purpose of this study is to evaluate the efficiency of zanubrutinib combined with R-CHOP regimen in newly diagnosed primary intraocular lymphoma.
- Trial name
- NCT04899570
- Testing
- Zanubrutinib, Rituximab, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
This is a phase 2 multi-cohort, un-controlled, non-randomized, open-label, multi-center study that assessed the antitumor activity and safety of non-alpha interleukin (IL-2) SAR444245 with or without other anticancer therapies in…
- Trial name
- NCT05179603
- Testing
- THOR-707, Pembrolizumab
- Where
- 8 sites in Argentina, Chile and 1 more
- Volunteers
- 14 people
- Sponsor
- Sanofi
Diffuse Large B Cell Lymphoma
Frontline of ASCT in High-risk DLBCL
The role of frontline therapy of autologous stem cell transplant (ASCT) in diffuse large B-cell lymphoma (DLBCL) is controversial.
- Trial name
- Essential (NCT05831865)
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Peking University People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.